Skip to the page

Data / Drug companies / Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories, LLC: 102 products in the FDA NDC directory, labeler code 0832

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Upsher-Smith Laboratories, LLC (labeler code 0832) lists 102 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 102 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 8, 2026.

The request: Watch Upsher-Smith Laboratories, LLC (FDA labeler code 0832): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0832
Products in commercial distribution
102
Packages
177
Finished drugs by generic name
38
Prescription products
102
Over the counter products
0
Controlled substance products
Schedule II 9, Schedule III 2, Schedule IV 2
Flagged as original packager
84 of 84 products that carry the flag
Started marketing in the last 12 months
6
Products with a marketing end date set
31
Earliest marketing start
April 17, 1986
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)9391.2%
Authorized generics (NDA)76.9%
New drug applications (NDA)22%

Products by type

TypeProductsShare
Prescription drugs102100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet4241.2%
Capsule, extended release1817.6%
Tablet, film coated1211.8%
Tablet, extended release54.9%
Capsule, liquid filled43.9%
Solution/ drops32.9%
Tablet, delayed release32.9%
Tablet, film coated, extended release22%
Capsule22%
Injection, solution22%
Emulsion11%
Capsule, gelatin coated11%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Brimonidine Tartrate0832-1435Solution/ dropsGeneric drugs (ANDA)September 8, 2026
Fluvoxamine Maleate0832-6026Capsule, extended releaseGeneric drugs (ANDA)May 15, 2026
Fluvoxamine Maleate0832-6025Capsule, extended releaseGeneric drugs (ANDA)April 30, 2026
Glatiramer Acetate0832-6085Injection, solutionGeneric drugs (ANDA)January 23, 2026
Glatiramer Acetate0832-6084Injection, solutionGeneric drugs (ANDA)January 23, 2026
Ciprofloxacin and Dexamethasone0832-1430SuspensionGeneric drugs (ANDA)January 6, 2026
Difluprednate0832-6054EmulsionGeneric drugs (ANDA)February 21, 2025
Deflazacort0832-0817TabletGeneric drugs (ANDA)November 5, 2024
Deflazacort0832-0816TabletGeneric drugs (ANDA)November 5, 2024
Deflazacort0832-0815TabletGeneric drugs (ANDA)November 5, 2024
Deflazacort0832-0814TabletGeneric drugs (ANDA)November 5, 2024
Brimonidine Tartrate0832-1420Solution/ dropsGeneric drugs (ANDA)June 12, 2024
Imatinib mesylate0832-0533TabletGeneric drugs (ANDA)May 17, 2024
Imatinib mesylate0832-0532TabletGeneric drugs (ANDA)May 17, 2024
Pitavastatin0832-6050TabletGeneric drugs (ANDA)November 2, 2023
Pitavastatin0832-6049TabletGeneric drugs (ANDA)November 2, 2023
Pitavastatin0832-6048TabletGeneric drugs (ANDA)November 2, 2023
Famotidine0832-6045Powder, for suspensionGeneric drugs (ANDA)June 16, 2023
Mesalamine0832-6056Capsule, extended releaseGeneric drugs (ANDA)June 6, 2023
Brimonidine Tartrate and Timolol Maleate0832-1425Solution/ dropsGeneric drugs (ANDA)December 15, 2022
Fluphenazine Hydrochloride0832-6006Tablet, film coatedGeneric drugs (ANDA)November 22, 2022
Fluphenazine Hydrochloride0832-6005Tablet, film coatedGeneric drugs (ANDA)November 22, 2022
Fluphenazine Hydrochloride0832-6004Tablet, film coatedGeneric drugs (ANDA)November 22, 2022
Fluphenazine Hydrochloride0832-6003Tablet, film coatedGeneric drugs (ANDA)November 22, 2022
Fluoxetine hydrochloride0832-6032For solutionGeneric drugs (ANDA)November 15, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.